Abstract
Resistance to endocrine therapy in breast cancer is common. With the aim of discovering new molecular targets for breast cancer therapy, we have recently identified LMTK3 as a regulator of the estrogen receptor-alpha (ERα) and wished to understand its role in endocrine resistance. We find that inhibition of LMTK3 in a xenograft tamoxifen (Tam)-resistant (BT474) breast cancer mouse model results in re-sensitization to Tam as demonstrated by a reduction in tumor volume. A whole genome microarray analysis, using a BT474 cell line, reveals genes significantly modulated (positively or negatively) after LMTK3 silencing, including some that are known to be implicated in Tam resistance, notably c-MYC, HSPB8 and SIAH2. We show that LMTK3 is able to increase the levels of HSPB8 at a transcriptional and translational level thereby protecting MCF7 cells from Tam-induced cell death, by reducing autophagy. Finally, high LMTK3 levels at baseline in tumors are predictive for endocrine resistance; therapy does not lead to alteration in levels, whereas in patient’s plasma samples, acquired LMTK3 gene amplification (copy number variation) was associated with relapse while receiving Tam. In aggregate, these data support a role for LMTK3 in both innate (intrinsic) and acquired (adaptive) endocrine resistance in breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
CRUK. http://cancerhelp.cancerresearchuk.org/type/breast-cancer/ 2012.
Cordera F, Jordan VC . Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol 2006; 33: 631–641.
Dixon JM, Rodger A, Stebbing J . Breast cancer (non-metastatic). Clin Evid 2005; 13: 2226–2257.
Stebbing J, Delaney G, Thompson A . Breast cancer (non-metastatic). Clin Evid 2007; 2007.
Stebbing J, Stearns V, Davidson NE . Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics 2007; 8: 1–3.
Schafer JM, Jordan VC . Models of hormone resistance in vitro and in vivo. Methods Mol Med 2006; 120: 453–464.
Ali S, Coombes RC . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101–112.
Giamas G, Man YL, Hirner H, Bischof J, Kramer K, Khan K et al. Kinases as targets in the treatment of solid tumors. Cell Signal 2010; 22: 984–1002.
Giamas G, Stebbing J, Vorgias CE, Knippschild U . Protein kinases as targets for cancer treatment. Pharmacogenomics 2007; 8: 1005–1016.
Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011; 17: 715–719.
Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, Pearlberg J et al. High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci USA. 2011; 108: 2058–2063.
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y et al. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 120: 639–648.
Chow LW, Yip AY, Loo WT, Lam CK, Toi M . Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008; 111: 13–17.
Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 2012; 22: 220–231.
Lasfargues EY, Coutinho WG, Redfield ES . Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 1978; 61: 967–978.
Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 2009; 16: 413–424.
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010; 16: 214–218.
Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A et al. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 2011, epub ahead of print 08 November 2011.
Harrington WR, Sengupta S, Katzenellenbogen BS . Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology 2006; 147: 3843–3850.
Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008; 27: 3021–3031.
Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 17: 2024–2034.
Guo S, RR Gonzalez-Perez . Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS One 2011; 6: e21467.
Rizzo P, Miao H, D′Souza G, Osipo C, Song LL, Yun J et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008; 68: 5226–5235.
Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME et al. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. Breast Cancer Res Treat 2009; 116: 263–271.
Tomura H, Mogi C, Sato K, Okajima F . Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. Cell Signal 2005; 17: 1466–1476.
Xu Y, Zhu K, Hong G, Wu W, Baudhuin LM, Xiao Y et al. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol 2000; 2: 261–267.
Stone JC . Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells. Genes Cancer 2011; 2: 320–334.
Liguori L, Andolfo I, de Antonellis P, Aglio V, di Dato V, Marino N et al. The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. Cell Cycle 2012; 11: 569–581.
Wilson CG, Robert-Cooperman CE, Burkhardt BR . PANcreatic-DERived factor: novel hormone PANDERing to glucose regulation. FEBS Lett 2011; 585: 2137–2143.
Oshima T, Fujino T, Ando K, Hayakawa M . Role of FGD1, a Cdc42 guanine nucleotide exchange factor, in epidermal growth factor-stimulated c-Jun NH2-terminal kinase activation and cell migration. Biol Pharm Bull 2011; 34: 54–60.
Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G . Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 2011; 11: 417.
Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 2008; 8: 154.
Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM . INPP4B: the new kid on the PI3K block. Oncotarget 2011; 2: 321–328.
Fedele CG, Ooms LM, Ho M, Vieusseux J, O′Toole SA, Millar EK et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA. 2010; 107: 22231–22236.
Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S . SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol 2011; 25: 72–82.
Xu J, Wan M, He Q, Bassett RL, Fu X, Chen AC et al. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat 2012.
Sun X, Fontaine JM, Bartl I, Behnam B, Welsh MJ, Benndorf R . Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptor-positive breast cancer cells. Cell Stress Chaperones 2007; 12: 307–319.
Cook KL, Shajahan AN, Clarke R . Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther 2011; 11: 1283–1294.
Lange CA, Yee D . Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 2011; 18: C19–C24.
Miller TW, Balko JM, Arteaga CL . Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011; 29: 4452–4461.
Musgrove EA, Sutherland RL . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631–643.
Osborne CK, Schiff R . Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011; 62: 233–247.
Hu DG, Mackenzie PI . Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. Mol Pharmacol 2009; 76: 425–439.
Kappe G, Franck E, Verschuure P, Boelens WC, Leunissen JA, de Jong WW . The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10. Cell Stress Chaperones 2003; 8: 53–61.
Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D . Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006; 66: 3903–3911.
Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954–11966.
Stebbing J, Filipovic A, Ellis IO, Green AR, D′Silva TR, Lenz HJ et al. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat 2012; 132: 537–544.
Acknowledgements
We would like to thank Champions Biotechnology, in particular David Sidransky and Elizabeth Bruckheimer for their expertise and help with the mouse xenograft model (Johns Hopkins, Baltimore, USA), P Trivedi for performing the immunohistochemistry staining (Imperial College) and Katsuhiko Ono for technical assistance (Tohoku University). We are grateful to Richard Szydlo (Imperial College) for statistical advice. We thank Martina Sperling for performing the Illumina microarray hybridizations. We thank Luisella Toschi, Anette Sommer, and Georg Beckmann (Bayer, Berlin, Germany) for their significant input in both the experimental design and analysis of the gene expression profiling experiments and the selection of cell lines, without which this work could not have been undertaken. The project was supported by a grant from the Grants for Targets (G4T) program of Bayer Healthcare. JS, JAS, RCC and GG are supported by grants from Cancer Research UK. This work has been supported by a UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant to GG. We thank R & E Girling and friends, Cancer Research UK and the Pink Ribbon Foundation for their support. This work was also supported by the Imperial BRC and ECMC.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Stebbing, J., Filipovic, A., Lit, L. et al. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene 32, 3371–3380 (2013). https://doi.org/10.1038/onc.2012.343
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.343
Keywords
This article is cited by
-
Diving into the dark kinome: lessons learned from LMTK3
Cancer Gene Therapy (2022)
-
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
Oncogene (2019)
-
Structure-Based Virtual Screening of High-Affinity ATP-Competitive Inhibitors Against Human Lemur Tyrosine Kinase-3 (LMTK3) Domain: A Novel Therapeutic Target for Breast Cancer
Interdisciplinary Sciences: Computational Life Sciences (2019)
-
LMTK3 confers chemo-resistance in breast cancer
Oncogene (2018)
-
The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8
Acta Pharmacologica Sinica (2018)